Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact

CD37 keeps B cell lymphoma at bay

B cell non-Hodgkin lymphoma is the most prevalent hematological disease worldwide. Enhanced, autocrine IL-6 signaling has been observed in B lymphoma cells from patients, and therapeutic approaches targeting the IL-6 pathway are currently under investigation. However, the molecular events that cause the altered IL-6 signaling are still unknown. Charlotte de Winde, Sharon Veenbergen, and colleagues at Radboud University Medical Center report that CD37 plays a critical role in regulating IL-6 signaling in B lymphoma cells. Using CD37-deficient mice, the group demonstrated that loss of CD37 expression results in spontaneous, multiple-organ lymphoma that consists of IgA+, germinal center-like B cells. Adoptive transfer of CD37-deficient lymphoma cells to CD37-deficient or lymphocyte-deficient recipient mice induced new tumors with metastatic potential. Moreover, loss of CD37 expression corresponded with enhanced IL-6 signaling in B lymphoma cells, as evidenced by increased phosphorylation of the downstream mediators AKT and STAT3 and increased IL-6 production. Mice deficient in both CD37 and IL-6 were protected from lymphoma, further confirming that CD37 regulates the IL-6 signaling that facilitates disease development. The authors determined that CD37 deficiency promotes IL-6 signaling due to loss of CD37 binding to SOCS3, which inhibits SOCS3-mediated suppression of the IL-6 pathway. Evaluation of diseased tissue from patients with diffuse large B cell lymphoma revealed that IL-6 expression is enhanced in tumors that lack CD37 expression, and patients with CD37-deficent tumors exhibited worse overall survival than patients with CD37-expressing tumors. These findings indicate a molecular mechanism that controls tumor-promoting IL-6 signaling in spontaneous B cell lymphoma. The accompanying image shows immunohistochemistry staining of CD37 (red) in human lymphoma tissue (cell nuclei counterstained with hematoxylin in blue). The 4 panels correspond to tissue from 4 diffuse large B cell lymphoma patients. Note that tumors either exhibited ubiquitous CD37 expression (2 upper panels) or lacked CD37 expression (2 lower panels).

Published January 19, 2016, by Elizabeth Wong

Scientific Show StopperOncology

Related articles

Tetraspanin CD37 protects against the development of B cell lymphoma
Charlotte M. de Winde, … , Carl G. Figdor, Annemiek B. van Spriel
Charlotte M. de Winde, … , Carl G. Figdor, Annemiek B. van Spriel
Published January 19, 2016
Citation Information: J Clin Invest. 2016;126(2):653-666. https://doi.org/10.1172/JCI81041.
View: Text | PDF
Research Article Oncology

Tetraspanin CD37 protects against the development of B cell lymphoma

  • Text
  • PDF
Abstract

Worldwide, B cell non-Hodgkin lymphoma is the most common hematological malignancy and represents a substantial clinical problem. The molecular events that lead to B cell lymphoma are only partially defined. Here, we have provided evidence that deficiency of tetraspanin superfamily member CD37, which is important for B cell function, induces the development of B cell lymphoma. Mice lacking CD37 developed germinal center–derived B cell lymphoma in lymph nodes and spleens with a higher incidence than Bcl2 transgenic mice. We discovered that CD37 interacts with suppressor of cytokine signaling 3 (SOCS3); therefore, absence of CD37 drives tumor development through constitutive activation of the IL-6 signaling pathway. Moreover, animals deficient for both Cd37 and Il6 were fully protected against lymphoma development, confirming the involvement of the IL-6 pathway in driving tumorigenesis. Loss of CD37 on neoplastic cells in patients with diffuse large B cell lymphoma (DLBCL) directly correlated with activation of the IL-6 signaling pathway and with worse progression-free and overall survival. Together, this study identifies CD37 as a tumor suppressor that directly protects against B cell lymphomagenesis and provides a strong rationale for blocking the IL-6 pathway in patients with CD37– B cell malignancies as a possible therapeutic intervention.

Authors

Charlotte M. de Winde, Sharon Veenbergen, Ken H. Young, Zijun Y. Xu-Monette, Xiao-xiao Wang, Yi Xia, Kausar J. Jabbar, Michiel van den Brand, Alie van der Schaaf, Suraya Elfrink, Inge S. van Houdt, Marion J. Gijbels, Fons A.J. van de Loo, Miranda B. Bennink, Konnie M. Hebeda, Patricia J.T.A. Groenen, J. Han van Krieken, Carl G. Figdor, Annemiek B. van Spriel

×
Advertisement

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts